(600161)"BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600161 · · 16 pages · Chinese
Summary by 6ix AI
The report indicates a decline in revenue and net profit compared to the same period last year, attributed to changes in tax policy and product pricing. The total assets of the company have increased slightly, while the equity attributable to shareholders has also seen a modest rise. The report emphasizes the accuracy and completeness of the financial information provided, with no audit conducted for this quarter.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Beijing Tiantan Biological Products Corporation Limited on 6ix
Earlier from Beijing Tiantan Biological Products
- (600161)"BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD."Announcement on Obtaining the Clinical Study Report by Subordinate Company
- Announcement on Resolutions of the 4th Meeting of the 10th Board of Directors
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Obtaining the Plasmapheresis Licenses by Subsidiaries
- Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors
Later from Beijing Tiantan Biological Products
All Beijing Tiantan Biological Products news releasesFollow Beijing Tiantan Biological Products into a list and get an email when it puts out news.
Follow Beijing Tiantan Biological Products